Aligos Therapeutics (ALGS) Retained Earnings (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Retained Earnings for 8 consecutive years, with -$666.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings fell 12.85% year-over-year to -$666.7 million; the trailing twelve-month figure through Jun 2026 stood at -$666.7 million (down 12.85% YoY), and the FY2025 full-year result was -$642.2 million, down 3.91% from the prior year.
• Retained Earnings was little changed at -$666.7 million in Q2 2026 per ALGS's latest filing, from -$665.2 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$338.7 million in Q1 2022 and bottomed at -$666.7 million in Q2 2026.
• Historically, Retained Earnings has averaged -$513.2 million across 5 years, with a median of -$519.2 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings plunged 67.33% in 2022, then fell 3.91% in 2025.
• Over 5 years, Retained Earnings stood at -$399.1 million in 2022, then dropped by 21.97% to -$486.8 million in 2023, then retreated by 26.95% to -$618.0 million in 2024, then decreased by 3.91% to -$642.2 million in 2025, then slipped by 3.82% to -$666.7 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$666.7 million, -$665.2 million, and -$642.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.